Reading ASMB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ASMB free→Reading ASMB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ASMB free→QuarterlyIQ Insights · ASMB
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
The filing pertains to stockholder-approved amendments to the company's incentive plans.
Entry into a Material Definitive Agreement. On May 21, 2026, Assembly Biosciences, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Guggenheim Securities, LLC ("Guggenheim Securities") and UBS Securities LLC, as representatives of the several underwriters listed in Schedule A thereto (the "Underwriters"), in connection with the issuance and sale, in an underwritten, registered offering (the "Offering"), of: (1) 3,358,602 shares (the "Offering Sha…
Results of Operations and Financial Condition. On May 7, 2026, Assembly Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabil…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On March 24, 2026, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Assembly Biosciences, Inc. (the “Company”) approved a new cash bonus plan, the 2026 Corporate Bonus Plan (the “Plan”). The Plan is effective as of January 1, 2026 and is designed to motivate, retain, attract and reward employees through a…
Results of Operations and Financial Condition. On March 19, 2026, Assembly Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subjec…
Results of Operations and Financial Condition. On November 10, 2025, Assembly Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to…
Unregistered Sales of Equity Securities. The information set forth in
Other Events. On August 8, 2025, the Company issued a press release announcing the pricing of the Offering and Private Placement. A copy of such press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Entry into a Material Definitive Agreement Underwritten Offering On August 8, 2025, Assembly Biosciences, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Guggenheim Securities, LLC (“Guggenheim Securities”), as representative of the several underwriters listed in Schedule A thereto (the “ Underwriters ”), in connection with the issuance and sale, in an underwritten, registered offering (the “ Offering ”), of: (1) 5,591,840 shares of the Comp…
Results of Operations and Financial Condition. On August 6, 2025, Assembly Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liab…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amendment No. 1 and Amendment No. 2 to Amended and Restated 2018 Stock Incentive Plan At the Assembly Biosciences, Inc. (the “Company”) Annual Meeting of Stockholders held on June 5, 2025 (the “Annual Meeting”), the Company’s stockholders approved Amendment No. 1 (“Amendment No. 1”) to the Assembly Biosciences, Inc. Amended and Restated 2018 Stock…
Results of Operations and Financial Condition. On May 8, 2025, Assembly Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that se…
Results of Operations and Financial Condition. On March 20, 2025, Assembly Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subjec…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.